Cognition Life Science Appoints Dr. Chuanhai Cao As Chief Scientific Officer

TAMPA, Fla., Jan. 13, 2016 /PRNewswire/ -- Cognition Life Science, Inc. (CLS), a new pharmaceutical company located in Tampa, Florida, announced today the appointment of Dr. Chuanhai Cao as its Chief Scientific Officer and the acquisition of his intellectual property. Dr. Chuanhai Cao's intellectual property includes novel formulations intended to treat Alzheimer's Disease, Parkinson's Disease, Sleep Disorders and Mental Acuity.

Dr. Chuanhai Cao was one of the first scientists in the world to determine that THC can halt and reverse the symptoms of Alzheimer's Disease. Dr. Cao is a well-known researcher who developed a therapeutic vaccine for the treatment of Alzheimer's disease and for certain forms of cancer. Under the terms of the agreements CLS has issued Dr. Cao 13.5 million of its common shares and is obligated to pay Dr. Cao $5 million upon certain milestone achievements. Dr. Cao will be spending a portion of his time attending to his duties at CLS and will be responsible for a budget, which is expected to be in excess of $1 million.

Dr. Chuanhai Cao is a research scientist at the College of Medicine Neurology and Assistant Professor of Cop. Department of Pharmaceutical Science at USF/Byrd Institute in Tampa, Florida.

Alzheimer's Disease is the most popular form of dementia and affects approximately 30 million people worldwide. At the present time, there are no approved drugs to either slow or halt the progression of Alzheimer's disease. Dr. Chuanhai Cao believes that our new experimental formulation may be the first of its kind to succeed where other formulations have failed.

Parkinson's Disease affects the nerve cells in the brain that produce dopamine. There is presently no cure. Approximately 7 - 10 million suffer from Parkinson's disease worldwide.

Sleep disorder affects tens of millions of people. Sales of both Rx and OTC products are in excess of $20 billion a year. Dr. Chuanhai Cao has developed a formulation that has been shown to induce sleep in as little as 3 1/2 minutes. The formulation is non-narcotic.

Mental Acuity often declines with age. This is a condition which is suffered by tens of millions of seniors. It is not considered a disease process. There are products, mostly sold over the counter, that are intended to improve memory and cognition.

About USF/BYRD Institute - The USF/Byrd Institute is dedicated to the prevention, diagnosis, treatment and care of Alzheimer's disease and related disorders. USF/Byrd have a national and international reputation for excellent research and patient care.

About Dr. Chuanhai Cao Dr. Cao received his PhD in medical biology at Tianjin China. He is a prolific inventor and has published many peer reviewed articles. Dr. Cao has been quoted by the Huffington Post and appeared on Dr. Sanjay Gupta's television program on the medical use of cannabis.

About Cognition Life Science, Inc. Cognition Life Science, Inc. is a privately held new pharmaceutical company which was formed to explore, acquire and develop proprietary formulations to treat neurodegenerative diseases, sleep disorder, mental acuity and pain management. The company establishes relationships with researchers and accredited laboratories/institutions and explores new ways to deliver existing generic compounds as well as combining natural ingredients which have been shown to be safe and effective. Certain formulations include THC.

For more information, contact:


1302 19th Street, suite 200. Tampa, Florida 33605

813 - 563 0544

Rene de Wit , on behalf of the board.

To view the original version on PR Newswire, visit:

SOURCE Cognition Life Science, Inc.